Conference sponsors | The Primary Care Respiratory Society UK
 
 

   Inspiring best practice in respiratory care

   

This website is for healthcare professionals only

Conference sponsors

Conference Sponsors

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com
   
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine www.boehringer-ingelheim.co.uk
   
Chiesi Limited is a family-owned company with a reputation for research and innovation. In 2014 Chiesi had an R&D turnover in excess of 16% and the Chiesi pipeline currently includes over 40 projects at various stages of development. Chiesi specialises in respiratory, neonatal and rare diseases with well-known treatments for asthma, COPD, cystic fibrosis and respiratory distress syndrome in premature neonates. Chiesi is committed to improving patient outcomes and quality of life, and recent innovations include a novel dry powder inhaler with features designed to enhance patient experience for people living with asthma and COPD.
   
GSK is a science-led global healthcare company with a mission to help people do more, feel better and live longer. For more than 45 years, GSK has been a leader in respiratory, helping patients with respiratory disease better manage their condition. Working in collaboration with the scientific community, we remain at the cutting-edge of scientific research into innovative medicines with the aim of helping to treat patients’ symptoms and reduce the risk of their disease. For further information please visit www.gsk.com.
   
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com
   

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global healthcare portfolio includes biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Please visit the Pfizer stand to hear more about smoking cessation and the Pfizer alliances with Novartis and Bristol-Myers Squibb and how we collaborate to improve the wellbeing of patients living with COPD and cardiovascular disease in the United Kingdom.